Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging | 98 | 2021 | 1328 | 11.220 |
Why?
|
Magnetic Resonance Imaging, Cine | 47 | 2020 | 103 | 8.910 |
Why?
|
Ventricular Function, Left | 46 | 2021 | 245 | 8.010 |
Why?
|
Ventricular Dysfunction, Left | 37 | 2021 | 170 | 7.720 |
Why?
|
Stroke Volume | 45 | 2021 | 348 | 7.310 |
Why?
|
Dobutamine | 29 | 2018 | 69 | 6.480 |
Why?
|
Anthracyclines | 13 | 2020 | 62 | 6.440 |
Why?
|
Heart Ventricles | 32 | 2018 | 135 | 5.840 |
Why?
|
Exercise Test | 32 | 2021 | 227 | 5.210 |
Why?
|
Heart Diseases | 15 | 2021 | 116 | 5.060 |
Why?
|
Antineoplastic Agents | 15 | 2020 | 608 | 5.020 |
Why?
|
Heart Failure | 32 | 2021 | 639 | 4.680 |
Why?
|
Cardiovascular Diseases | 31 | 2021 | 1128 | 4.610 |
Why?
|
Myocardial Ischemia | 20 | 2018 | 107 | 4.510 |
Why?
|
Neoplasms | 16 | 2020 | 728 | 4.390 |
Why?
|
Antibiotics, Antineoplastic | 12 | 2019 | 74 | 4.160 |
Why?
|
Myocardium | 25 | 2019 | 186 | 3.790 |
Why?
|
Middle Aged | 136 | 2021 | 11839 | 3.130 |
Why?
|
Predictive Value of Tests | 48 | 2019 | 876 | 2.950 |
Why?
|
Aged | 125 | 2021 | 10314 | 2.860 |
Why?
|
Humans | 202 | 2021 | 32114 | 2.750 |
Why?
|
Myocardial Contraction | 12 | 2016 | 63 | 2.660 |
Why?
|
Exercise Tolerance | 11 | 2021 | 125 | 2.570 |
Why?
|
Male | 145 | 2021 | 19217 | 2.480 |
Why?
|
Female | 145 | 2021 | 20015 | 2.460 |
Why?
|
Atherosclerosis | 31 | 2017 | 766 | 2.430 |
Why?
|
Cardiotonic Agents | 12 | 2015 | 48 | 2.430 |
Why?
|
Risk Assessment | 33 | 2021 | 1429 | 2.230 |
Why?
|
Aorta, Thoracic | 13 | 2019 | 85 | 2.130 |
Why?
|
Prognosis | 37 | 2018 | 1497 | 2.060 |
Why?
|
Doxorubicin | 8 | 2019 | 82 | 2.020 |
Why?
|
Magnetic Resonance Angiography | 14 | 2015 | 77 | 2.010 |
Why?
|
Myocardial Infarction | 16 | 2018 | 475 | 1.980 |
Why?
|
Risk Factors | 43 | 2020 | 3880 | 1.940 |
Why?
|
Coronary Artery Disease | 16 | 2018 | 401 | 1.930 |
Why?
|
Aged, 80 and over | 64 | 2020 | 3990 | 1.930 |
Why?
|
Contrast Media | 16 | 2015 | 138 | 1.910 |
Why?
|
Hypertrophy, Left Ventricular | 11 | 2019 | 120 | 1.900 |
Why?
|
Ventricular Remodeling | 12 | 2019 | 58 | 1.900 |
Why?
|
Coronary Circulation | 14 | 2016 | 43 | 1.900 |
Why?
|
Myocardial Perfusion Imaging | 4 | 2016 | 27 | 1.850 |
Why?
|
Time Factors | 27 | 2020 | 2151 | 1.810 |
Why?
|
Chest Pain | 5 | 2019 | 208 | 1.800 |
Why?
|
Diagnostic Imaging | 9 | 2015 | 94 | 1.750 |
Why?
|
Aortic Diseases | 8 | 2015 | 63 | 1.710 |
Why?
|
Emergency Service, Hospital | 5 | 2019 | 474 | 1.710 |
Why?
|
Prospective Studies | 40 | 2021 | 2283 | 1.700 |
Why?
|
Cardiomyopathies | 10 | 2018 | 56 | 1.700 |
Why?
|
Aorta | 9 | 2015 | 126 | 1.650 |
Why?
|
Coronary Vessels | 8 | 2017 | 165 | 1.500 |
Why?
|
Ethnic Groups | 17 | 2017 | 476 | 1.500 |
Why?
|
Breast Neoplasms | 7 | 2020 | 765 | 1.410 |
Why?
|
Heart | 11 | 2019 | 177 | 1.370 |
Why?
|
Cardiovascular System | 3 | 2018 | 43 | 1.330 |
Why?
|
Adult | 50 | 2020 | 9380 | 1.320 |
Why?
|
Cardiotoxins | 2 | 2018 | 8 | 1.230 |
Why?
|
Cardiac Output | 4 | 2019 | 36 | 1.220 |
Why?
|
Radiation Injuries | 3 | 2019 | 76 | 1.210 |
Why?
|
Electrocardiography | 17 | 2021 | 605 | 1.110 |
Why?
|
Cardiology | 6 | 2020 | 99 | 1.080 |
Why?
|
Echocardiography | 14 | 2019 | 159 | 1.080 |
Why?
|
Echocardiography, Stress | 6 | 2016 | 27 | 1.060 |
Why?
|
Intra-Abdominal Fat | 5 | 2018 | 63 | 1.030 |
Why?
|
Coronary Disease | 9 | 2015 | 211 | 1.010 |
Why?
|
Hematologic Neoplasms | 2 | 2015 | 35 | 0.980 |
Why?
|
Medical Oncology | 3 | 2020 | 86 | 0.980 |
Why?
|
Fibrosis | 10 | 2021 | 120 | 0.950 |
Why?
|
Aging | 9 | 2016 | 946 | 0.940 |
Why?
|
Hypertension | 6 | 2021 | 960 | 0.930 |
Why?
|
Acute Coronary Syndrome | 4 | 2019 | 196 | 0.920 |
Why?
|
Ventricular Function, Right | 4 | 2013 | 17 | 0.910 |
Why?
|
Mitral Valve Insufficiency | 4 | 2018 | 25 | 0.890 |
Why?
|
Sex Factors | 9 | 2017 | 667 | 0.870 |
Why?
|
Isolated Noncompaction of the Ventricular Myocardium | 4 | 2015 | 5 | 0.850 |
Why?
|
Pulmonary Edema | 2 | 2014 | 11 | 0.850 |
Why?
|
Heptanoic Acids | 2 | 2014 | 29 | 0.830 |
Why?
|
Blood Flow Velocity | 8 | 2011 | 77 | 0.820 |
Why?
|
Adipose Tissue | 4 | 2014 | 349 | 0.810 |
Why?
|
Pyrroles | 2 | 2014 | 55 | 0.810 |
Why?
|
Hemodynamics | 8 | 2015 | 155 | 0.810 |
Why?
|
Age Factors | 14 | 2018 | 1189 | 0.790 |
Why?
|
Organometallic Compounds | 3 | 2010 | 23 | 0.760 |
Why?
|
Health Status Indicators | 1 | 2021 | 73 | 0.730 |
Why?
|
Survivors | 3 | 2018 | 163 | 0.730 |
Why?
|
Heart Neoplasms | 1 | 2020 | 18 | 0.730 |
Why?
|
Cardiac Volume | 4 | 2017 | 13 | 0.730 |
Why?
|
Coronary Stenosis | 3 | 2016 | 30 | 0.710 |
Why?
|
Vasodilator Agents | 4 | 2014 | 62 | 0.700 |
Why?
|
Reproducibility of Results | 12 | 2017 | 765 | 0.690 |
Why?
|
Coronary Angiography | 12 | 2015 | 153 | 0.680 |
Why?
|
Edema, Cardiac | 2 | 2016 | 13 | 0.670 |
Why?
|
United States | 32 | 2019 | 3976 | 0.670 |
Why?
|
Pericardium | 4 | 2014 | 52 | 0.670 |
Why?
|
Oxygen Consumption | 11 | 2021 | 154 | 0.670 |
Why?
|
Endothelium, Vascular | 6 | 2018 | 156 | 0.660 |
Why?
|
Models, Cardiovascular | 6 | 2016 | 32 | 0.630 |
Why?
|
Image Enhancement | 6 | 2015 | 72 | 0.620 |
Why?
|
Arteries | 3 | 2009 | 67 | 0.600 |
Why?
|
Population Surveillance | 4 | 2017 | 125 | 0.590 |
Why?
|
Linear Models | 12 | 2019 | 449 | 0.590 |
Why?
|
Obesity, Abdominal | 2 | 2015 | 24 | 0.590 |
Why?
|
Collagen | 1 | 2018 | 225 | 0.580 |
Why?
|
Adrenergic beta-Agonists | 3 | 2009 | 30 | 0.570 |
Why?
|
Adiposity | 2 | 2016 | 198 | 0.560 |
Why?
|
Disease Progression | 6 | 2018 | 594 | 0.550 |
Why?
|
Gadolinium | 4 | 2015 | 22 | 0.550 |
Why?
|
Prediabetic State | 2 | 2015 | 65 | 0.540 |
Why?
|
Atropine | 8 | 2011 | 22 | 0.540 |
Why?
|
Case-Control Studies | 8 | 2021 | 898 | 0.540 |
Why?
|
Angina Pectoris | 3 | 2018 | 22 | 0.530 |
Why?
|
Patient Positioning | 1 | 2015 | 23 | 0.520 |
Why?
|
Stress, Physiological | 2 | 2016 | 55 | 0.520 |
Why?
|
Abdominal Fat | 2 | 2018 | 50 | 0.510 |
Why?
|
Bilirubin | 1 | 2015 | 25 | 0.510 |
Why?
|
Follow-Up Studies | 13 | 2017 | 2265 | 0.510 |
Why?
|
Echocardiography, Doppler | 8 | 2021 | 45 | 0.490 |
Why?
|
Simvastatin | 1 | 2014 | 25 | 0.490 |
Why?
|
Tubulin Modulators | 1 | 2014 | 10 | 0.490 |
Why?
|
Severity of Illness Index | 11 | 2019 | 881 | 0.480 |
Why?
|
Incidence | 11 | 2018 | 1199 | 0.480 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 753 | 0.480 |
Why?
|
Subcutaneous Fat | 2 | 2015 | 47 | 0.480 |
Why?
|
Observer Variation | 9 | 2017 | 105 | 0.470 |
Why?
|
Renal Circulation | 1 | 2014 | 13 | 0.470 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 12 | 0.470 |
Why?
|
Furosemide | 1 | 2014 | 9 | 0.470 |
Why?
|
Continental Population Groups | 6 | 2017 | 237 | 0.470 |
Why?
|
North Carolina | 6 | 2015 | 1538 | 0.460 |
Why?
|
Ventricular Function | 4 | 2012 | 7 | 0.460 |
Why?
|
Renal Artery | 1 | 2014 | 47 | 0.460 |
Why?
|
Prevalence | 10 | 2019 | 989 | 0.460 |
Why?
|
Renal Artery Obstruction | 1 | 2014 | 41 | 0.460 |
Why?
|
Retrospective Studies | 12 | 2019 | 3510 | 0.450 |
Why?
|
Blood Glucose | 3 | 2015 | 494 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 12 | 2015 | 919 | 0.440 |
Why?
|
Cardiology Service, Hospital | 1 | 2013 | 23 | 0.440 |
Why?
|
Cross-Sectional Studies | 10 | 2017 | 1542 | 0.430 |
Why?
|
Oxygen | 1 | 2014 | 142 | 0.430 |
Why?
|
Disability Evaluation | 1 | 2014 | 240 | 0.430 |
Why?
|
Leukemia | 1 | 2013 | 40 | 0.430 |
Why?
|
Lymphoma | 1 | 2013 | 35 | 0.430 |
Why?
|
Multivariate Analysis | 8 | 2016 | 684 | 0.430 |
Why?
|
Heterocyclic Compounds | 2 | 2010 | 12 | 0.430 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 145 | 0.430 |
Why?
|
Cohort Studies | 18 | 2019 | 1817 | 0.420 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 246 | 0.420 |
Why?
|
Heart Rate | 7 | 2017 | 335 | 0.420 |
Why?
|
Diastole | 11 | 2021 | 96 | 0.410 |
Why?
|
Hospitalization | 4 | 2020 | 470 | 0.410 |
Why?
|
Atrial Function, Left | 1 | 2012 | 18 | 0.400 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2016 | 226 | 0.400 |
Why?
|
Gadolinium DTPA | 3 | 2012 | 16 | 0.390 |
Why?
|
Sensitivity and Specificity | 7 | 2014 | 582 | 0.390 |
Why?
|
Hospital Costs | 1 | 2011 | 38 | 0.380 |
Why?
|
Health Expenditures | 1 | 2011 | 66 | 0.380 |
Why?
|
Patient Admission | 1 | 2011 | 60 | 0.380 |
Why?
|
Obesity | 6 | 2021 | 1176 | 0.370 |
Why?
|
Inpatients | 1 | 2011 | 85 | 0.370 |
Why?
|
Angina, Unstable | 4 | 2015 | 21 | 0.370 |
Why?
|
Reference Values | 11 | 2016 | 246 | 0.360 |
Why?
|
Heart Function Tests | 3 | 2010 | 9 | 0.360 |
Why?
|
Chi-Square Distribution | 5 | 2015 | 297 | 0.360 |
Why?
|
Health Care Costs | 2 | 2010 | 118 | 0.360 |
Why?
|
Societies, Medical | 7 | 2015 | 164 | 0.350 |
Why?
|
Bicycling | 1 | 2009 | 14 | 0.350 |
Why?
|
Animals | 12 | 2019 | 7542 | 0.340 |
Why?
|
Delivery of Health Care | 1 | 2011 | 161 | 0.340 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2009 | 53 | 0.340 |
Why?
|
Meglumine | 1 | 2009 | 4 | 0.340 |
Why?
|
Fluorocarbons | 2 | 1999 | 21 | 0.340 |
Why?
|
Femoral Artery | 3 | 2009 | 50 | 0.330 |
Why?
|
Infusions, Intravenous | 6 | 2012 | 100 | 0.330 |
Why?
|
Women's Health Services | 1 | 2009 | 11 | 0.330 |
Why?
|
Systole | 10 | 2018 | 99 | 0.330 |
Why?
|
Advisory Committees | 3 | 2015 | 31 | 0.330 |
Why?
|
Image Interpretation, Computer-Assisted | 5 | 2017 | 112 | 0.330 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 140 | 0.330 |
Why?
|
C-Reactive Protein | 5 | 2020 | 238 | 0.320 |
Why?
|
Glucose Intolerance | 1 | 2009 | 46 | 0.320 |
Why?
|
Medical Records | 1 | 2009 | 76 | 0.320 |
Why?
|
Lower Extremity | 1 | 2009 | 100 | 0.320 |
Why?
|
Estrogen Replacement Therapy | 1 | 2010 | 199 | 0.320 |
Why?
|
Longitudinal Studies | 6 | 2020 | 770 | 0.310 |
Why?
|
Heart Valve Diseases | 2 | 2007 | 27 | 0.290 |
Why?
|
Leg | 2 | 2006 | 65 | 0.290 |
Why?
|
Regional Blood Flow | 3 | 2015 | 86 | 0.290 |
Why?
|
Heart Defects, Congenital | 1 | 2007 | 31 | 0.280 |
Why?
|
Kidney | 1 | 2010 | 518 | 0.270 |
Why?
|
Death, Sudden, Cardiac | 2 | 2003 | 62 | 0.270 |
Why?
|
Radiotherapy | 2 | 2018 | 82 | 0.270 |
Why?
|
Vasodilation | 5 | 2013 | 94 | 0.270 |
Why?
|
Heart Atria | 2 | 2010 | 65 | 0.260 |
Why?
|
Troponin | 2 | 2019 | 106 | 0.260 |
Why?
|
Blood Pressure | 7 | 2013 | 845 | 0.260 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 145 | 0.250 |
Why?
|
Exercise | 3 | 2014 | 673 | 0.250 |
Why?
|
Myocytes, Cardiac | 3 | 2019 | 86 | 0.230 |
Why?
|
Sex Characteristics | 4 | 2019 | 173 | 0.230 |
Why?
|
Drug Administration Schedule | 3 | 2014 | 276 | 0.230 |
Why?
|
Adenosine | 6 | 2011 | 59 | 0.220 |
Why?
|
Carotid Artery Diseases | 2 | 2015 | 114 | 0.220 |
Why?
|
Calcinosis | 2 | 2010 | 146 | 0.220 |
Why?
|
Aneurysm, False | 1 | 2003 | 14 | 0.210 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 190 | 0.210 |
Why?
|
Ventricular Dysfunction, Right | 2 | 2015 | 18 | 0.210 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2020 | 66 | 0.210 |
Why?
|
Algorithms | 4 | 2017 | 495 | 0.210 |
Why?
|
European Continental Ancestry Group | 6 | 2017 | 1166 | 0.200 |
Why?
|
Intraoperative Complications | 1 | 2002 | 56 | 0.200 |
Why?
|
Cardiac-Gated Imaging Techniques | 4 | 2019 | 18 | 0.200 |
Why?
|
Early Diagnosis | 2 | 2013 | 62 | 0.200 |
Why?
|
Smoking | 3 | 2015 | 528 | 0.200 |
Why?
|
Peptide Fragments | 3 | 2020 | 399 | 0.190 |
Why?
|
American Heart Association | 5 | 2014 | 87 | 0.190 |
Why?
|
Inflammation | 2 | 2015 | 530 | 0.190 |
Why?
|
Feasibility Studies | 2 | 2017 | 294 | 0.190 |
Why?
|
Length of Stay | 2 | 2013 | 314 | 0.190 |
Why?
|
Analysis of Variance | 4 | 2016 | 464 | 0.190 |
Why?
|
African Americans | 5 | 2020 | 1425 | 0.180 |
Why?
|
Comorbidity | 2 | 2016 | 566 | 0.180 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 517 | 0.180 |
Why?
|
Radiography | 5 | 2010 | 376 | 0.180 |
Why?
|
Rats | 3 | 2018 | 1596 | 0.180 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 519 | 0.180 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 65 | 0.170 |
Why?
|
Atrial Fibrillation | 2 | 2010 | 322 | 0.170 |
Why?
|
Pulmonary Artery | 2 | 1999 | 24 | 0.170 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2019 | 4 | 0.170 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2009 | 12 | 0.160 |
Why?
|
Body Mass Index | 5 | 2015 | 923 | 0.160 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 35 | 0.160 |
Why?
|
Muscle Proteins | 1 | 2019 | 59 | 0.160 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2019 | 58 | 0.160 |
Why?
|
Receptors, Neurokinin-1 | 1 | 2018 | 3 | 0.160 |
Why?
|
Rats, Inbred SHR | 1 | 2018 | 31 | 0.160 |
Why?
|
Rats, Wistar | 1 | 2018 | 79 | 0.160 |
Why?
|
Muscular Atrophy | 1 | 2019 | 71 | 0.160 |
Why?
|
Atrophy | 1 | 2018 | 46 | 0.160 |
Why?
|
Body Fat Distribution | 1 | 2018 | 34 | 0.160 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2018 | 5 | 0.160 |
Why?
|
Procollagen | 1 | 2018 | 7 | 0.160 |
Why?
|
Ultrasonography | 8 | 2013 | 379 | 0.150 |
Why?
|
Random Allocation | 1 | 2018 | 228 | 0.150 |
Why?
|
Fibroblasts | 1 | 2018 | 111 | 0.150 |
Why?
|
Models, Animal | 1 | 2018 | 169 | 0.150 |
Why?
|
Collagen Type I | 1 | 2018 | 42 | 0.150 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2018 | 83 | 0.150 |
Why?
|
Microcirculation | 2 | 2016 | 65 | 0.150 |
Why?
|
Injections, Intraperitoneal | 2 | 2019 | 45 | 0.150 |
Why?
|
Mitral Valve | 1 | 2018 | 32 | 0.150 |
Why?
|
Myocardial Revascularization | 2 | 2013 | 41 | 0.150 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 201 | 0.150 |
Why?
|
Automation | 1 | 2017 | 31 | 0.150 |
Why?
|
Practice Guidelines as Topic | 4 | 2014 | 408 | 0.150 |
Why?
|
Pain Measurement | 1 | 2019 | 350 | 0.150 |
Why?
|
Peptides | 1 | 2018 | 120 | 0.150 |
Why?
|
Heart Failure, Diastolic | 1 | 2017 | 15 | 0.150 |
Why?
|
Spironolactone | 1 | 2017 | 11 | 0.150 |
Why?
|
Stress, Mechanical | 1 | 2017 | 92 | 0.150 |
Why?
|
Lysine | 1 | 2017 | 23 | 0.140 |
Why?
|
African Continental Ancestry Group | 2 | 2017 | 363 | 0.140 |
Why?
|
Brachial Artery | 2 | 2014 | 69 | 0.140 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 33 | 0.140 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2018 | 15 | 0.140 |
Why?
|
Atrial Function | 2 | 2010 | 3 | 0.140 |
Why?
|
Diet, Mediterranean | 1 | 2016 | 31 | 0.130 |
Why?
|
Statistics as Topic | 2 | 2009 | 108 | 0.130 |
Why?
|
Double-Blind Method | 3 | 2017 | 525 | 0.130 |
Why?
|
Aorta, Abdominal | 2 | 2014 | 29 | 0.130 |
Why?
|
Idarubicin | 1 | 2015 | 7 | 0.130 |
Why?
|
Daunorubicin | 1 | 2015 | 27 | 0.130 |
Why?
|
Aortography | 1 | 2015 | 16 | 0.130 |
Why?
|
Lung Neoplasms | 1 | 2019 | 414 | 0.130 |
Why?
|
Disease Models, Animal | 3 | 2019 | 1022 | 0.130 |
Why?
|
Survival Rate | 2 | 2017 | 877 | 0.130 |
Why?
|
Rats, Sprague-Dawley | 2 | 2018 | 743 | 0.130 |
Why?
|
Quality of Life | 5 | 2013 | 946 | 0.120 |
Why?
|
Papillary Muscles | 1 | 2014 | 2 | 0.120 |
Why?
|
Weight Loss | 1 | 2018 | 480 | 0.120 |
Why?
|
Calcium | 1 | 1996 | 307 | 0.120 |
Why?
|
Carotid Arteries | 3 | 2013 | 99 | 0.120 |
Why?
|
Organ Size | 5 | 2016 | 218 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2015 | 317 | 0.120 |
Why?
|
Patient Compliance | 1 | 2016 | 225 | 0.120 |
Why?
|
Genetic Testing | 1 | 2015 | 96 | 0.120 |
Why?
|
Extracellular Matrix | 1 | 2016 | 245 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2015 | 52 | 0.120 |
Why?
|
Body Surface Area | 2 | 2014 | 15 | 0.120 |
Why?
|
Radiation Dosage | 3 | 2010 | 84 | 0.120 |
Why?
|
Mass Screening | 1 | 1996 | 263 | 0.120 |
Why?
|
Disease Management | 1 | 2015 | 126 | 0.120 |
Why?
|
Treatment Outcome | 4 | 2014 | 3306 | 0.120 |
Why?
|
Oxidative Stress | 1 | 2015 | 231 | 0.110 |
Why?
|
Fibrinogen | 1 | 2013 | 44 | 0.110 |
Why?
|
Administration, Oral | 1 | 2014 | 187 | 0.110 |
Why?
|
Troponin I | 1 | 2013 | 22 | 0.110 |
Why?
|
Observation | 1 | 2013 | 25 | 0.110 |
Why?
|
Data Collection | 2 | 2015 | 182 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2014 | 257 | 0.110 |
Why?
|
Heart Failure, Systolic | 1 | 2012 | 15 | 0.110 |
Why?
|
Clinical Competence | 4 | 2015 | 333 | 0.110 |
Why?
|
Mobility Limitation | 1 | 2014 | 219 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2015 | 210 | 0.100 |
Why?
|
Interleukin-6 | 1 | 2013 | 247 | 0.100 |
Why?
|
Phantoms, Imaging | 2 | 2010 | 60 | 0.100 |
Why?
|
Radionuclide Imaging | 1 | 2011 | 26 | 0.100 |
Why?
|
Patient Readmission | 1 | 2013 | 126 | 0.100 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2012 | 37 | 0.100 |
Why?
|
Models, Economic | 1 | 2011 | 20 | 0.100 |
Why?
|
Body Composition | 2 | 2010 | 397 | 0.100 |
Why?
|
Cost Savings | 1 | 2011 | 34 | 0.100 |
Why?
|
Elasticity | 3 | 2013 | 36 | 0.100 |
Why?
|
Recurrence | 2 | 2003 | 263 | 0.100 |
Why?
|
Drug Costs | 1 | 2011 | 47 | 0.100 |
Why?
|
Ventricular Pressure | 2 | 2021 | 5 | 0.090 |
Why?
|
Thigh | 2 | 2018 | 42 | 0.090 |
Why?
|
Acute Disease | 1 | 2011 | 253 | 0.090 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2010 | 12 | 0.090 |
Why?
|
Radiopharmaceuticals | 1 | 2011 | 93 | 0.090 |
Why?
|
History, 21st Century | 1 | 2010 | 59 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2010 | 26 | 0.090 |
Why?
|
History, 20th Century | 1 | 2010 | 71 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2013 | 270 | 0.090 |
Why?
|
Enalapril | 1 | 2010 | 8 | 0.090 |
Why?
|
Hispanic Americans | 5 | 2009 | 940 | 0.090 |
Why?
|
Foundations | 1 | 2010 | 8 | 0.090 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2010 | 13 | 0.090 |
Why?
|
Periodicals as Topic | 1 | 2011 | 91 | 0.090 |
Why?
|
Medroxyprogesterone | 1 | 2010 | 14 | 0.090 |
Why?
|
Patient Discharge | 1 | 2011 | 188 | 0.090 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 28 | 0.090 |
Why?
|
Sex Distribution | 3 | 2016 | 191 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 100 | 0.090 |
Why?
|
Age Distribution | 3 | 2016 | 206 | 0.090 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 39 | 0.090 |
Why?
|
Body Height | 1 | 2010 | 34 | 0.090 |
Why?
|
Anthropometry | 1 | 2010 | 83 | 0.090 |
Why?
|
Tissue Survival | 1 | 2009 | 12 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2010 | 67 | 0.090 |
Why?
|
Iliac Artery | 1 | 2009 | 49 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 135 | 0.080 |
Why?
|
Computer Simulation | 1 | 2010 | 220 | 0.080 |
Why?
|
Adolescent | 4 | 2001 | 3568 | 0.080 |
Why?
|
Muscle Contraction | 1 | 2009 | 114 | 0.080 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2008 | 2 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 288 | 0.080 |
Why?
|
Young Adult | 2 | 2013 | 2665 | 0.080 |
Why?
|
Single-Blind Method | 2 | 2013 | 203 | 0.080 |
Why?
|
Capillaries | 1 | 2008 | 24 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2009 | 72 | 0.080 |
Why?
|
Quadriceps Muscle | 1 | 2008 | 34 | 0.080 |
Why?
|
Health Policy | 1 | 2008 | 89 | 0.080 |
Why?
|
Diabetes Complications | 2 | 2006 | 177 | 0.080 |
Why?
|
Odds Ratio | 2 | 2015 | 472 | 0.080 |
Why?
|
Vasomotor System | 1 | 1988 | 22 | 0.080 |
Why?
|
Body Weight | 1 | 2010 | 310 | 0.080 |
Why?
|
Up-Regulation | 2 | 2019 | 189 | 0.080 |
Why?
|
Patient Selection | 3 | 2010 | 276 | 0.080 |
Why?
|
Postmenopause | 1 | 2010 | 430 | 0.070 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 352 | 0.070 |
Why?
|
Cerebrovascular Circulation | 1 | 1988 | 93 | 0.070 |
Why?
|
Transplants | 1 | 2007 | 23 | 0.070 |
Why?
|
Tachycardia, Ventricular | 1 | 2006 | 14 | 0.070 |
Why?
|
Rest | 1 | 2006 | 53 | 0.070 |
Why?
|
Death | 1 | 2006 | 49 | 0.070 |
Why?
|
Ischemia | 1 | 2006 | 98 | 0.070 |
Why?
|
Medical Staff Privileges | 1 | 2005 | 2 | 0.060 |
Why?
|
Risk | 1 | 2006 | 321 | 0.060 |
Why?
|
Thiazoles | 1 | 2005 | 27 | 0.060 |
Why?
|
Torsion, Mechanical | 2 | 2016 | 6 | 0.060 |
Why?
|
Vascular Resistance | 1 | 2004 | 31 | 0.060 |
Why?
|
Inflammation Mediators | 2 | 2015 | 104 | 0.060 |
Why?
|
Arteriosclerosis | 1 | 2004 | 123 | 0.060 |
Why?
|
Survival Analysis | 2 | 2016 | 483 | 0.060 |
Why?
|
Asian Americans | 3 | 2009 | 97 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 633 | 0.060 |
Why?
|
Angiography | 2 | 2013 | 80 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2004 | 143 | 0.050 |
Why?
|
Respiration | 3 | 1996 | 27 | 0.050 |
Why?
|
Stimulation, Chemical | 1 | 2001 | 13 | 0.050 |
Why?
|
Mississippi | 1 | 2020 | 27 | 0.050 |
Why?
|
Lung Diseases, Obstructive | 1 | 2000 | 5 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2004 | 412 | 0.040 |
Why?
|
Cell Size | 1 | 2019 | 38 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2019 | 101 | 0.040 |
Why?
|
Arteriovenous Malformations | 1 | 1999 | 8 | 0.040 |
Why?
|
Pulmonary Veins | 1 | 1999 | 10 | 0.040 |
Why?
|
Echocardiography, Transesophageal | 2 | 1999 | 42 | 0.040 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2000 | 53 | 0.040 |
Why?
|
Troponin T | 1 | 2020 | 81 | 0.040 |
Why?
|
Polysomnography | 1 | 2019 | 40 | 0.040 |
Why?
|
Independent Living | 1 | 2019 | 100 | 0.040 |
Why?
|
Hematopoiesis | 1 | 2018 | 33 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2018 | 143 | 0.040 |
Why?
|
Compliance | 2 | 2010 | 13 | 0.040 |
Why?
|
Cell Survival | 1 | 2018 | 285 | 0.040 |
Why?
|
Consensus | 1 | 2018 | 85 | 0.040 |
Why?
|
Gene Expression | 1 | 2019 | 338 | 0.040 |
Why?
|
Muscle Strength | 1 | 2018 | 161 | 0.040 |
Why?
|
Texas | 1 | 2017 | 36 | 0.040 |
Why?
|
Registries | 2 | 2009 | 298 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 186 | 0.040 |
Why?
|
Radionuclide Ventriculography | 1 | 1996 | 1 | 0.040 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 132 | 0.030 |
Why?
|
Apoptosis | 1 | 2018 | 360 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 767 | 0.030 |
Why?
|
Laser-Doppler Flowmetry | 1 | 1996 | 31 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2015 | 21 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2015 | 68 | 0.030 |
Why?
|
Indicator Dilution Techniques | 1 | 1995 | 2 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2015 | 80 | 0.030 |
Why?
|
Oximetry | 1 | 1995 | 31 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 560 | 0.030 |
Why?
|
Adipokines | 1 | 2015 | 16 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2016 | 100 | 0.030 |
Why?
|
Cause of Death | 1 | 2016 | 236 | 0.030 |
Why?
|
Vascular Patency | 1 | 1995 | 69 | 0.030 |
Why?
|
Cotinine | 1 | 2015 | 49 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 175 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2014 | 149 | 0.030 |
Why?
|
Regression Analysis | 1 | 2014 | 293 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 125 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 127 | 0.030 |
Why?
|
Medicare | 1 | 1995 | 206 | 0.030 |
Why?
|
Thoracic Surgical Procedures | 1 | 2013 | 13 | 0.030 |
Why?
|
Mice | 1 | 2019 | 2484 | 0.030 |
Why?
|
Health Surveys | 1 | 2013 | 198 | 0.030 |
Why?
|
Logistic Models | 1 | 2015 | 783 | 0.030 |
Why?
|
Dilatation, Pathologic | 1 | 2012 | 20 | 0.030 |
Why?
|
Perfusion | 1 | 2011 | 73 | 0.020 |
Why?
|
Peer Review, Research | 1 | 2011 | 9 | 0.020 |
Why?
|
Decision Making | 1 | 2014 | 195 | 0.020 |
Why?
|
Journal Impact Factor | 1 | 2011 | 11 | 0.020 |
Why?
|
Editorial Policies | 1 | 2011 | 15 | 0.020 |
Why?
|
Europe | 1 | 2010 | 82 | 0.020 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2010 | 10 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2010 | 16 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2010 | 81 | 0.020 |
Why?
|
Software | 1 | 2011 | 123 | 0.020 |
Why?
|
Elastic Modulus | 1 | 2010 | 28 | 0.020 |
Why?
|
Probability | 1 | 2010 | 159 | 0.020 |
Why?
|
Postoperative Period | 1 | 2010 | 97 | 0.020 |
Why?
|
Waist Circumference | 1 | 2010 | 90 | 0.020 |
Why?
|
Fasting | 1 | 2009 | 95 | 0.020 |
Why?
|
Accreditation | 1 | 2009 | 16 | 0.020 |
Why?
|
Triglycerides | 1 | 2009 | 230 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2009 | 81 | 0.020 |
Why?
|
Verapamil | 1 | 1988 | 8 | 0.020 |
Why?
|
Arterioles | 1 | 1988 | 13 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2009 | 158 | 0.020 |
Why?
|
Wakefulness | 1 | 1988 | 25 | 0.020 |
Why?
|
Acetylcholine | 1 | 1988 | 48 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2010 | 390 | 0.020 |
Why?
|
Rabbits | 1 | 1988 | 197 | 0.020 |
Why?
|
Homeostasis | 1 | 1988 | 132 | 0.020 |
Why?
|
Asian Continental Ancestry Group | 1 | 2006 | 108 | 0.020 |
Why?
|
Dogs | 2 | 1996 | 120 | 0.020 |
Why?
|
Credentialing | 1 | 2005 | 9 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 392 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2005 | 55 | 0.020 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 22 | 0.020 |
Why?
|
Plethysmography | 1 | 2004 | 15 | 0.020 |
Why?
|
ROC Curve | 1 | 2004 | 164 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2005 | 142 | 0.010 |
Why?
|
Ergometry | 1 | 2002 | 5 | 0.010 |
Why?
|
Natriuretic Agents | 1 | 2002 | 3 | 0.010 |
Why?
|
Atrial Natriuretic Factor | 1 | 2002 | 10 | 0.010 |
Why?
|
Catecholamines | 1 | 2002 | 18 | 0.010 |
Why?
|
Physical Endurance | 1 | 2002 | 36 | 0.010 |
Why?
|
Diabetic Nephropathies | 1 | 2004 | 224 | 0.010 |
Why?
|
Dipyridamole | 1 | 2001 | 3 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 2001 | 23 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2001 | 73 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2004 | 543 | 0.010 |
Why?
|
Rheology | 1 | 1995 | 30 | 0.010 |
Why?
|